Caption Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Caption Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$390K	–	1566
2025 Q4	$390K	Buy	50,000 +1,800	+4%	+$13K	﹤0.01%	1283
2025 Q3	$366K	Buy	48,200 +28,200	+141%	+$235K	﹤0.01%	1373
2025 Q2	$179K	Buy	+20,000	New	+$186K	﹤0.01%	1272
2025 Q1	–	Sell	-296,500	Closed	-$2.23M	–	1523
2024 Q4	$2.23M	Buy	+296,500	New	+$2.25M	0.02%	654
2024 Q3	–	Sell	-72,100	Closed	-$446K	–	1278
2024 Q2	$446K	Buy	72,100 +22,100	+44%	+$122K	0.01%	828
2024 Q1	$254K	Hold	50,000	–	–	﹤0.01%	973
2023 Q4	$300K	Sell	50,000 -12,500	-20%	-$72.4K	﹤0.01%	1059
2023 Q3	$443K	Buy	+62,500	New	+$449K	0.01%	961
2023 Q2	–	Sell	-40,000	Closed	-$334K	–	1104
2023 Q1	$334K	Sell	40,000 -40,000	-50%	-$385K	0.01%	863
2022 Q4	$918K	Buy	80,000 +10,000	+14%	+$125K	0.01%	775
2022 Q3	$881K	Hold	70,000	–	–	0.01%	904
2022 Q2	$741K	Sell	70,000 -17,500	-20%	-$181K	0.01%	979
2022 Q1	$1.42M	Buy	87,500 +32,500	+59%	+$521K	0.02%	853
2021 Q4	$764K	Sell	55,000 -275,000	-83%	-$3.64M	0.01%	1139
2021 Q3	$4.74M	Sell	330,000 -90,800	-22%	-$1.43M	0.05%	478
2021 Q2	$6.66M	Buy	420,800 +170,800	+68%	+$2.32M	0.09%	301
2021 Q1	$2.54M	Buy	+250,000	New	+$2.58M	0.05%	446
2020 Q1	–	Sell	-368,700	Closed	-$1.27M	–	860
2019 Q4	$1.27M	Buy	+368,700	New	+$928K	0.04%	450

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caption Management's BCRX Position: Q1 2025 in Review

Caption Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 62,789 shares — an estimated $472K sold.

Caption Management first reported a position in BCRX in Q1 2019 and held it in 13 quarters. The position peaked at $7.98M in Q2 2021. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

Caption Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Caption Management sold 62,789 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $472K.
Caption Management first reported a position in BioCryst Pharmaceuticals in Q1 2019 and held it in 13 quarters.
Caption Management's BioCryst Pharmaceuticals position peaked at $7.98M in Q2 2021.
274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.